tiprankstipranks
BSF’s Kerato Ltd Advances Corneal Damage Treatment
Company Announcements

BSF’s Kerato Ltd Advances Corneal Damage Treatment

BSF Enterprise PLC (GB:BSFA) has released an update.

Pick the best stocks and maximize your portfolio:

BSF Enterprise PLC, through its subsidiary Kerato Ltd, has partnered with the University of Montreal to develop an innovative in-situ gelling cornea treatment for corneal damage, which could dramatically simplify procedures and improve patient outcomes. The new therapy will leverage tissue engineering to create a treatment that reduces hospital time, costs, and graft rejection rates, and is expected to initially be tested in veterinary cases. This aligns with Kerato’s goal to commercialize their tissue engineering intellectual property and expand into clinical and veterinary trials.

For further insights into GB:BSFA stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskBSF Enterprise’s 3DBT Secures Grant to Advance Lab-Grown Leather
TipRanks UK Auto-Generated NewsdeskBSF Enterprise Subsidiary Secures Grant to Advance Lab-Grown Leather
TipRanks UK Auto-Generated NewsdeskBSF Enterprise Raises £500,000 for Strategic Growth
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App